GoAI
Get started
Scienture Holdings, Inc. logo

Scienture Holdings, Inc.

SCNX

NASDAQHealthcareMedical - Pharmaceuticals

Open in GoAI

Previous close

$0.4497

−$0.0221 · -4.68%

Aug 21, 4:00 PM ET

SCNX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

10

Overpriced

Momentum

35

Weakening

Sentiment

58

Mixed

Risk resilience

9

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute a broad spectrum of products and services, encompassing branded and generic drugs as well as other non-pharmaceutical items. Customers for these offerings span government organizations, hospitals, medical clinics, and independent pharmacies. The firm's corporate base is situated in Tampa, Florida.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
US
CEO
Shankar Hariharan
Listed since
Feb 6, 2014
Employees
9

Market position

Day range

Current $0.4497

52-week range

Current $0.4497

Open
$0.48
Previous close
$0.4718
Volume
215.14K
0.11× average
Average volume
1.88M
Average daily volume
Market cap
18.27M USD
Beta
3.96
Market reference 1
50-day average
$0.3899
+15.33% above average
200-day average
$0.4514
-0.38% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
71.63M USD
P/E (TTM)
-0.24×
P/B (TTM)
0×
P/S (TTM)
22.25×
EV / EBITDA
-1.84×
Earnings yield
-53.04%
Free cash flow yield
-17097.57%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
30.73%
Operating margin
-1671.08%
Net margin
-4620.92%
Return on equity
-59.20%
Return on assets
-49.31%
Return on invested capital
-19.03%

Financial health

Debt / equity
0.17×
Current ratio
2.89×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends8374%1417%-5541%-12498%Gross margin, FY2021: 47.99%Gross margin, FY2022: 53.85%Gross margin, FY2023: 3.60%Gross margin, FY2024: 4.39%Gross margin, FY2025: 76.80%Operating margin, FY2021: -53.51%Operating margin, FY2022: -28.45%Operating margin, FY2023: -322.36%Operating margin, FY2024: -10758.70%Operating margin, FY2025: -3763.78%Net margin, FY2021: -53.75%Net margin, FY2022: -33.87%Net margin, FY2023: -1308.34%Net margin, FY2024: 6634.66%Net margin, FY2025: -9618.03%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 47.99%. Gross margin FY2022 53.85%. Gross margin FY2023 3.60%. Gross margin FY2024 4.39%. Gross margin FY2025 76.80%. Operating margin FY2021 -53.51%. Operating margin FY2022 -28.45%. Operating margin FY2023 -322.36%. Operating margin FY2024 -10758.70%. Operating margin FY2025 -3763.78%. Net margin FY2021 -53.75%. Net margin FY2022 -33.87%. Net margin FY2023 -1308.34%. Net margin FY2024 6634.66%. Net margin FY2025 -9618.03%.

Income trends

Revenue

431.61K USD+215.87%

Operating income

−16.24M USD-10.50%

Net income

−41.51M USD−50.58M USD
Income trends across reported periods15.43M USD−5.28M USD−25.98M USD−46.69M USDRevenue, FY2021: 9.89M USDRevenue, FY2022: 10.25M USDRevenue, FY2023: 1.36M USDRevenue, FY2024: 136.64K USDRevenue, FY2025: 431.61K USDOperating income, FY2021: −5.29M USDOperating income, FY2022: −2.92M USDOperating income, FY2023: −4.4M USDOperating income, FY2024: −14.7M USDOperating income, FY2025: −16.24M USDNet income, FY2021: −5.32M USDNet income, FY2022: −3.47M USDNet income, FY2023: −17.84M USDNet income, FY2024: 9.07M USDNet income, FY2025: −41.51M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 9.89M USD. Revenue FY2022 10.25M USD. Revenue FY2023 1.36M USD. Revenue FY2024 136.64K USD. Revenue FY2025 431.61K USD. Operating income FY2021 −5.29M USD. Operating income FY2022 −2.92M USD. Operating income FY2023 −4.4M USD. Operating income FY2024 −14.7M USD. Operating income FY2025 −16.24M USD. Net income FY2021 −5.32M USD. Net income FY2022 −3.47M USD. Net income FY2023 −17.84M USD. Net income FY2024 9.07M USD. Net income FY2025 −41.51M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue431.61K USD136.64K USD1.36M USD10.25M USD9.89M USD
Cost of goods sold100.13K USD130.64K USD1.31M USD4.73M USD5.14M USD
Gross profit331.48K USD6.01K USD49.03K USD5.52M USD4.75M USD
Research and development1.96M USD2.24M USD100.28K USD993.19K USD899.71K USD
Selling, general, and administrative14.52M USD12.05M USD4.45M USD6.57M USD7.54M USD
Operating expenses16.58M USD14.71M USD4.45M USD8.44M USD10.04M USD
Interest income302.7K USD135.34K USD4.2K USD20.99K USD—
Interest expense4.08M USD1.34M USD1.14M USD336.21K USD23.59K USD
Depreciation and amortization491.78K USD53.36K USD1.05M USD194.7K USD138.91K USD
Operating income−16.24M USD−14.7M USD−4.4M USD−2.92M USD−5.29M USD
Net income−41.51M USD9.07M USD−17.84M USD−3.47M USD−5.32M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
29%
2 beats, 5 misses, 0 met estimates
Average EPS surprise
-2105.60%
7 comparable reports
Latest EPS result
-0.07
Estimate -0.09 · Beat by 22.22%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.05-0.67-1.28-1.9Q1 '25No estimateQ2 '25No estimateQ3 '25No estimateQ4 '25No estimateQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 26, 2025: actual -0.819, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 12, 2025: actual -0.33, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 12, 2025: actual -0.48, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual -0.19, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 24, 2026: actual -1.76, estimate -0.22, surprise -700.00%, Miss. Q2 2026, reported May 11, 2026: actual -0.08, estimate -0.23, surprise +65.22%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.07, estimate -0.09, surprise +22.22%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.06, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.76M1.71M661.97K-385.39KQ4 '24MissQ1 '25MissQ2 '25No estimateQ4 '25No estimateQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q4 2024, reported Nov 6, 2024: actual 64.86K USD, estimate 2.48M USD, surprise -97.38%, Miss. Q1 2025, reported Mar 26, 2025: actual 53.08K USD, estimate 2.54M USD, surprise -97.91%, Miss. Q2 2025, reported May 12, 2025: actual 10.26K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual 590.05K USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 24, 2026: actual -168.7K USD, estimate 486.42K USD, surprise -134.68%, Miss. Q2 2026, reported May 11, 2026: actual 56.33K USD, estimate 400.98K USD, surprise -85.95%, Miss. Q3 2026, reported Aug 13, 2026: actual 343.64K USD, estimate 1.96M USD, surprise -82.50%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 1.58M USD, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Jun 22, 2023

1:15

SCNX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SCNX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
155.36K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
38.95K
Weight
—
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%

Continue in GoAI

Research SCNX

research.disclaimer